Novo Nordisk narrowed its earnings guidance as intensifying competition, pricing pressure and copycat versions of its ...

Diabetes and obesity care were a key growth driver, however the company lowered its expectations for growth, citing ...

For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

This article was reviewed by Lynn Marie Morski, MD, JD. How Long Does Ozempic® Stay in Your System? Key takeaways: Ozempic® ...

What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Americans are getting slimmer; Gallup says the obesity rate has decreased along with increased use of weight loss drugs such ...

This article was reviewed by Lynn Marie Morski, MD, JD. Does Ozempic® Cause Hair Loss? Key takeaways: Hair loss isn’t an ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...